COMPANY

About Us

iVIEW Therapeutics Inc. is a clinical stage ophthalmology drug development company.

Its lead compound iVIEW-1201 is starting global phase II human clinical trials in early 2019 for the treatment of viral conjunctivitis, which is an unmet medical need with no current FDA approved treatment.

iVIEW was established by serial entrepreneurs and clinical physicians and funded by reputable VCs and strategic corporate investors.
Headquartered in Pennsylvania Biotechnology Center in Doylestown, with over 1000 sq. ft. laboratories and offices.
China headquarter is located in Hengqin New District, Zhuhai City with a development/manufacturing base located in Wuhu City, Anhui Province.

We are building a solid product pipeline with both clinical and pre-clinical assets through both in-house innovation research and global product in-licensing.

Our novel drug development strategy centered in:
Novel extended-release formulations
Combination therapies based on existing FDA approved drugs
Exploring topical applications of NCEs or repurposed drugs with a focus on clinically validated targets

Our therapeutic focus and development strategy enabled us with unique market advantages.
Huge market potential & Safety profiles established.
Higher likelihood of clinical success due to focus on highly de-risked mechanisms/assets.
Combine cost-efficient pre-clinical research in China and ample clinical resources in US to expedite development.

Pennsylvania Biotechnology Center at Bucks County
3805 Old Easton Road
Doylestown PA 18902 USA
Copyright © 2019 iVIEW Therapeutics, Inc. All rights reserved.